Skip to content
The Nexus
DossierENTITY

Domenica Lorusso

Coverage of Domenica Lorusso in the Nexus archive.

Earliest in view: May 20 · 11:00 UTCMost recent: May 20 · 11:00 UTC
Co-mentioned in this coverage
Merckorganization1Brian Slomovitzperson1Mount Sinaiplace1Humanitas Universityplace1sacituzumab tirumotecantopic1
Recent coverage
  • HEALTHMay 20 · 11:00 UTCFOX NEWS
    New drug approach offers hope for patients with recurrent aggressive cancers

    A new treatment for endometrial cancer, sacituzumab tirumotecan, demonstrated strong potential in a Phase 3 clinical trial, meeting its primary endpoints of overall survival and progression-free survival. The trial involved 776 patients with advanced or recurrent endometrial cancer. The results show promise for addressing a critical unmet need for certain patients.